Is DBS-STN Appropriate to Treat Severe Parkinson Disease in an Elderly Population?
Neurol 68:1345-1355, Derost,P.-P.,et al, 2007

CNS Lupus: A Study of 41 Patients
Neurol 69:644-654, Joseph,F.G.,et al, 2007

Vascular Parkinsonism and Dementia in a CADASIL Case with Intact Nigrostriatal Dopaminergic System
Akt Neurol 33: Suppl, Wegner,F.,et al, 2006

Psychosis Related to Ropinirole
Am J Psychiatry 163:546-547, Perea,E.,et al, 2006

Mitochondrial DNA Polymerase-y and Human Disease
Hum Mol Genet 15:R244-R252, Hudson, G.,et al, 2006

Safety of Rasagiline in Elderly Patients with Parkinson Disease
Neurol 66:1427-1429, Goetz,C.G.,et al, 2006

Pesticide Exposure and Risk for Parkinsons Disease
Ann Neurol 60:197-203, Ascherio,A.,et al, 2006

Clinicopath Conf, Dopamine-Responsive-Dystonia Caused by a Mutation in the GCH1 Gene
NEJM 355:831-839, Case 26-2006, 2006

Atypical Antipsychotics in the Elderly with Parkinson Disease and the "Black Box" Warning
Neurol 67:564-566, Friedman,J.H., 2006

Neurologic Manifestations in Welders with Pallidal MRI T1 Hyperintensity
Neurol 64:2033-2039,2001, Josephs,K.A.,et al, 2005

Penetrance of the Fragile X-Associated Tremor/Ataxia Syndrome in a Premutation Carrier Population
JAMA 291:460-469, Jacquemont,S.,et al, 2004

Clinicopath Conf, Multiple-System Atrophy
NEJM 351:912-921, Case 27-2004, 2004

Ophthalmologic Features of Parkinson's Disease
Neurol 62:177-180, Biousse,V.,et al, 2004

Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Pract Neurology 4:50-55, Razvi,S.S.M. &Muir,K.W., 2004

Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003

Genetic, Clinical, and Radiographic Delineation of Hallervorden-Spatz Syndrome
NEJM 348:33-40, Hayflick,S.J.,et al, 2003

Parkinson Disease With Old-Age Onset
Arch Neurol 60:529-533, Diederich,N.J.,et al, 2003

Dementia with Lewy Bodies
Lancet 362:1689-1690, Wilcock,G.K., 2003

Welding-Related Parkinsonism
Neurol 56:8-13,4, Racette,B.A.,et al, 2001

Effects of Bilateral Subthalamic Stimulation on Cognitive Function in Parkinson Disease
Arch Neurol 58:1223-1227,1205, Alegret,M.,et al, 2001

Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000

The Brain lesion Responsible for Parkinsonism After Carbon Monoxide Poisnoning
Arch Neurol 57:1214-1218, Sohn,Y.H. et al, 2000

Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000

Niemann-Pick Disease Type C: Two Cases and an Update
Movement Disorders 15:1199-1203, Uc,E.Y.,et al, 2000

Diagnosing Dementia with Lewy Bodies
Lancet 354:1227-1228, McKeith,I.G.,et al, 1999

Acute and Reversible Parkinsonism Due to Organophosphate Pesticide Intoxication, Five Cases
Neurol 52:1467-1471, Bhatt,M.H.,et al, 1999

Prevalence and Clinical Correlates of Psychotic Symptoms in parkinson Disease
Arch Neurol 56:595-601, Aarsland,D.,et al, 1999

Transderm-induced Psychosis in Parkinson's Disease
Neurol 53:433-434, Minagar,A.,et al, 1999

Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999

An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998

Atrophy of the Corpus Callosum, Cortical Hypometabolism, and Cognitive Impairment in Corticobasal Degeneration
Arch Neurol 55:609-614, Yamauchi,H.,et al, 1998

Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998

The Risk of Parkinson's Disease with Exposure to Pesticides, Farming, Well Water, and Rural Living
Neurol 50:1346-1350, Gorell,J.M.,et al, 1998

Neuropsychological Consequences of Posteroventral Pallidotomy for the Treatment of Parkinson's Disease
Neurol 51:207-215, Trepanier,L.L.,et al, 1998

Cognitive Functioning After Pallidotomy for Refractory Parkinson's Disease
JNNP 65:150-154, 1481998., Perrine,K.,et al, 1998

Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998

Motor, Cognitive, and Behavioral Performance Following Unilateral Ventroposterior Pallidotomy for Parkinson Disease
Arch Neurol 55:1201-1208, Masterman,D.,et al, 1998

Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998

Subcotical Arteriosclerotic Encephalopathy (Binswangers Disease)
, Ghika,J. &Bogousslavsky, J., 1998

Unilateral Pallidotomy for Parkinson's Disease:Comparison of Outcome in Yonger Vs Elderly Patients
Neurol 49:1072-1077, Uitti,R.J.,et al, 1997

Occupational Exposures to Metals as Risk Factors for Parkinson's Disease
Neurol 48:650-658, Gorell,J.M.,et al, 1997

Comparison of Extrapyramidal Features in 31 Path Cases of Diffuse Lewy Body Disease & 34 Cases of Parkinson's
Neurol 48:376-380, Louis,E.D.,et al, 1997

P3 Latency Change in Aging and Parkinson Disease
Arch Neurol 54:296-302, Tachibana,H.,et al, 1997

Diagnosis of Chronic Manganese Intoxication by Magnetic Resonance Imaging
NEJM 336:965-966, Arjona,A.,et al, 1997

Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997

Clinical and Pathological Features in Hydrocarbon-Induced Parkinsonism
Ann Neurol 40:922-925, Pezzoli,G.,et al, 1996

Visual Hallucinations Associated with Parkinson Disease
Arch Neurol 53:1265-1268, Sanchez-Ramos,J.R.,et al, 1996

Neuropsychiatric Aspects of Progressive Supranuclear Palsy
Neurol 47:1184-1189, Litvan,I.,et al, 1996

Unusual Clinical Presentations of Cortical-Basal Ganglionic Degeneration
Ann Neurol 40:893-900, Bergeron,C.,et al, 1996

Bent Spine Syndrome
JNNP 60:51-54, Serratrice,G.,et al, 1996